Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal epidemiology of multiple sclerosis over 60 years in Newcastle, Australia: 1961 to 2021.

Multiple sclerosis and related disorders·2024
Same author

Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study.

BMJ neurology open·2024
Same author

Susac syndrome: a case report with initial presentation of incomplete bitemporal hemianopia.

Journal of surgical case reports·2023
Same author

Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022.

Multiple sclerosis and related disorders·2023
Same author

Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome.

European journal of neurology·2022
Same author

Response to treatment in NMOSD: the Australasian experience.

Multiple sclerosis and related disorders·2022
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
Same journal

Time-resolved GluCEST MRI of acute glutamate-related signal changes following kainic acid administration.

Journal of the neurological sciences·2026
Same journal

Sex differences in brain frailty measures and outcomes after endovascular thrombectomy: ESCAPE-NA1 analysis.

Journal of the neurological sciences·2026
Same journal

Neurophobia in context: Demographic and mental health correlates.

Journal of the neurological sciences·2026
Same journal

Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remission.

Journal of the neurological sciences·2026
Same journal

Central sensitization in long COVID: Associations with autonomic symptom burden, cerebral hypoperfusion, and neuroinflammation.

Journal of the neurological sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Immunosuppression followed by immunomodulation.

Mike Boggild1

  • 1The Walton Centre, Liverpool, UK. mikeboggild@thewaltoncentre.nhs.uk

Journal of the Neurological Sciences
|February 10, 2009
PubMed
Summary
This summary is machine-generated.

Induction therapy using mitoxantrone followed by glatiramer acetate (GA) maintenance may effectively manage aggressive relapsing remitting multiple sclerosis (RRMS). This approach offers a potentially synergistic treatment strategy with acceptable risks for RRMS patients.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Experiment Videos

Last Updated: Jun 25, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Emerging high-efficacy/high-risk therapies necessitate re-evaluation of current relapsing remitting multiple sclerosis (RRMS) treatment paradigms.
  • Patients with aggressive RRMS or early treatment failure require alternative therapeutic strategies beyond standard first-line treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of induction therapy with mitoxantrone followed by glatiramer acetate (GA) maintenance in RRMS.
  • To explore the potential synergistic effects of combining short-term immunosuppression with long-term immunomodulation for RRMS management.

Main Methods:

  • Investigated induction regimens combining short-course immunosuppressants (mitoxantrone) with maintenance therapy (glatiramer acetate).
  • Reviewed evidence on the effectiveness and risk profile of mitoxantrone induction followed by GA maintenance in RRMS patients.

Main Results:

  • Evidence suggests that brief mitoxantrone induction followed by GA maintenance may offer synergistic control of disease activity in RRMS.
  • This combination therapy appears to be administrable with an acceptable risk profile for managing aggressive RRMS.

Conclusions:

  • Mitoxantrone induction followed by GA maintenance presents a viable strategy for aggressive RRMS or cases with early treatment failure.
  • Physicians should reconsider treatment failure thresholds and the role of induction versus escalation strategies in RRMS management.